Pfizer and Boehringer-Ingelheim have been called before a federal court following a class action lawsuit for the negligent manufacture and distribution of Mirapex, a drug recently given to patients suffering from Parkinson’s disease and Restless Leg Syndrome. The lawsuit arose after two studies, one in 2003 by the Muhammad Ali Parkinson Research Center at Barrow Neurological Institute in Arizona and the second by the Mayo Clinic in 2005, found that patients treated with Mirapex developed compulsive behavior, including compulsive gambling and sexual behavior.
The lawsuit alleges that Pfizer and Boehringer-Ingelheim may have been aware of these side effects before releasing the drug but failed to list them in their report to the FDA. However, following the release of the studies, Pfizer and Boehringer began listing compulsive behaviors among possible side effects. The case has been designated for multidistrict litigation, meaning that all cases against Pfizer and Boehringer related to Mirapex will be brought before the Federal District Court in the Northern District of Minnesota. That court will be in charge of general discovery and preliminary matters related to Mirapex litigation. Cases that are filed in state court or another district will be transferred to the Northern District of Minnesota either through a motion by counsel or by the court’s own volition.
For more information, click here: